FDA 483 - Shire Human Genetic Therapies, Inc. - April 22, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Shire Human Genetic Therapies, Inc. in Lexington, MA, an Active Pharmaceutical Ingredient Manufacturer, received a Form 483 for a critical lapse in its Quality unit's oversight. The firm failed to adequately assess the impact of chromatography systems that had not undergone routine calibration since 2014 on the analytical testing of Velaglucerase Alfa and Idursulfase drug substances and products. This indicates a significant control deficiency that could impact product quality.
- Person
ID · 91b0c891-d7c9-41c4-856e-464b842ee491